HbA1c, Coronary atheroma progression and cardiovascular outcomes

Iryna Dykun; Ozgur Bayturan; Julie Carlo; Steven E Nissen; Samir R Kapadia; E Murat Tuzcu; Stephen J Nicholls; Rishi Puri

doi:10.1016/j.ajpc.2022.100317

HbA1c, Coronary atheroma progression and cardiovascular outcomes

Am J Prev Cardiol. 2022 Jan 18:9:100317. doi: 10.1016/j.ajpc.2022.100317. eCollection 2022 Mar.

Authors

Iryna Dykun^{1

2}, Ozgur Bayturan³, Julie Carlo¹, Steven E Nissen¹, Samir R Kapadia¹, E Murat Tuzcu⁴, Stephen J Nicholls⁵, Rishi Puri¹

Affiliations

¹ C5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
² Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.
³ Department of Cardiology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
⁴ Department of Cardiovascular Medicine, Cleveland Clinic Abu Dhabi, UAE.
⁵ Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia.

Abstract

Background and aims: We tested the hypothesis that on-treatment HbA1c levels independently associate with coronary atheroma progression and major adverse cardiovascular events (MACE: death, myocardial infarction, cerebrovascular accident, coronary revascularization, or hospitalization for unstable angina) rates.

Methods: We performed a post-hoc pooled analysis of data from seven prospective, randomized trials involving serial coronary intravascular ultrasonography (IVUS). The percent atheroma volume (PAV) was calculated as the proportion of the entire vessel wall occupied by atherosclerotic plaque. Using multivariable mixed modeling, we determined the association of on-treatment HbA1c with annualized change in PAV. Cox proportional hazard models were used to assess the association of HbA1c with incidence of MACE.

Results: Among 3,312 patients (mean age 58.6±9years, 28.4%women) average on-treatment HbA1c was 6.2±1.1%. Overall, there was no net significant annualized change in PAV (0.12±0.19%, p = 0.52). In a fully adjusted multivariable analysis (following adjustment of age, sex, body mass index, systolic blood pressure, smoking, low- and high-density lipoprotein cholesterol, triglyceride levels, peripheral vascular disease, trial, region, and baseline PAV), higher on-treatment HbA1c levels were independently associated with annualized changes in PAV [beta-estimate (95% confidence interval): 0.13(0.08, 0.19), p < 0.001]. On-treatment HbA1c levels were independently associated with MACE [hazard ratio (95% confidence interval): 1.13(1.04, 1.23), p = 0.005].

Conclusions: Independent of achieved cardiovascular risk factor control, greater HbA1c levels significantly associate with coronary atheroma progression rates and clinical outcomes. These results support the notion of a direct, specific effect of glycemic control upon coronary atheroma and atherosclerotic events, supporting the rationale of therapies designed to directly modulate it.

Keywords: ACS, acute coronary syndrome; AQUARIUS, Aliskiren Quantative Atherosclerosis Regression Intravascular Ultrasound Study; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CVD, cardiovascular disease; Coronary atheroma progression; Diabetes mellitus; GLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound; HDL-C, high-density lipoprotein cholesterol; HbA1c; HbA1c, hemoglobin A1c; IBIS 2, The Integrated Biomarkers and Imaging Study-2; IVUS; IVUS, intravascular ultrasonography; LDL-C, lipoprotein cholesterol; MACE; MACE, major adverse cardiovascular events; NORMALISE, Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation; PAV, percent atheroma volume; PERISCOPE, Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation; PVD, peripheral vascular disease; REVERSAL, Reversal of Atherosclerosis With Aggressive Lipid Lowering; SATURN, The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin; STRADIVARIUS, Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabont – The Intravascular Ultrasound Study; TG, triglycerides; UKPDS, UK Prospective Diabetes Study; hsCRP, high-sensitivity-CRP.